Galderma S.A.

Address: Zahlerweg 10

Sponsor Overview

assignment

Specializations

Atopic Dermatitis

Clinical research in atopic dermatitis centers on moderate-to-severe disease across pediatric, adolescent, and adult populations. The sponsor’s studies examine treatment needs in patients whose symptoms remain insufficiently controlled with topical therapy, with attention to ongoing disease management and long-term use.

Moderate-to-severe atopic dermatitis
Pediatric dermatology
Adolescent and adult skin disease
Topical corticosteroid use

The therapeutic focus includes chronic inflammatory skin disease, with interest in symptom control, tolerability, and sustained treatment safety.

Prurigo Nodularis

Research in prurigo nodularis addresses a chronic pruritic skin disorder marked by persistent itch and nodular lesions. The sponsor’s work in this area reflects interest in long-term treatment safety for patients living with ongoing dermatologic symptoms.

Chronic pruritus
Nodular skin lesions
Long-term dermatologic care
Symptom persistence

This area of study is closely tied to unmet needs in inflammatory itch-related skin disease.

Immunodermatology

The sponsor’s clinical portfolio points to interest in immune-mediated skin disease, especially conditions driven by chronic inflammation and itch. Research activity in this domain supports evaluation of therapies aimed at modifying disease burden in dermatologic disorders with an immunologic component.

Immune-mediated inflammation
Chronic itch
Inflammatory dermatoses
Dermatologic symptom burden

These interests align with treatment development for conditions where inflammation and pruritus are central clinical features.

Long-term Dermatologic Safety

A recurring theme in the sponsor’s research is long-term safety in chronic skin disease, including continued treatment exposure in patients requiring sustained management. The clinical focus includes monitoring tolerability over time in both younger and older populations.

Long-term safety
Tolerability
Chronic treatment exposure
Dermatology across age groups

This area reflects sustained interest in therapies intended for ongoing use in chronic inflammatory skin conditions.

Trial Name	Country	Status
Long-Term Safety and Efficacy Assessment of Nemolizumab (CD14152) in Moderate-to-Severe Atopic Dermatitis Patients	Austria Belgium Bulgaria Czechia Estonia France Germany Hungary Italy Latvia Lithuania Poland Spain The Netherlands	Not Recruiting
Long-Term Safety and Efficacy Assessment of Nemolizumab (CD14152) in Prurigo Nodularis Patients	Austria Belgium Denmark France Germany Hungary Italy Poland Spain Sweden The Netherlands	Not Recruiting
Pharmacokinetics, Safety, and Efficacy of Nemolizumab with Topical Corticosteroids in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis	Hungary Poland Spain	Not Recruiting
Phase 2 Randomized, Double‑Blind, Placebo‑Controlled, Dose‑Ranging Study of Subcutaneous Nemolizumab in Adults with Systemic Sclerosis Assessing Skin Thickness	Bulgaria Croatia France Greece Italy Poland Spain	Recruiting